公开(公告)号：US20230242503A9

公开(公告)日：2023-08-03

申请号：US17597939

申请日：2019-08-09

申请人： Artios Pharma Limited

发明人： Peter BLENCOWE ,  Mark CHARLES ,  Tennyson EKWURU ,  Harry FINCH ,  Robert HEALD ,  Hollie MCCARRON ,  Martin STOCKLEY

IPC分类号： C07D401/04 ,  A61K31/4439 ,  A61K45/06 ,  A61K31/5377 ,  C07D401/14 ,  A61K31/496 ,  C07D413/04 ,  C07D471/04 ,  A61K31/437 ,  C07D405/14 ,  C07D498/04 ,  A61K31/5383 ,  A61K31/541 ,  C07D417/14 ,  C07D491/04 ,  A61P35/00

CPC分类号： C07D401/04 ,  A61K31/4439 ,  A61K45/06 ,  A61K31/5377 ,  C07D401/14 ,  A61K31/496 ,  C07D413/04 ,  C07D471/04 ,  A61K31/437 ,  C07D405/14 ,  C07D498/04 ,  A61K31/5383 ,  A61K31/541 ,  C07D417/14 ,  C07D491/04 ,  A61P35/00

摘要： The application relates to heterocyclic amide derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation. (Formula (I))

公开(公告)号：US11690899B2

公开(公告)日：2023-07-04

申请号：US15557296

申请日：2016-03-10

申请人： Micreos Human Health B.V.

发明人： Fritz Eichenseher

IPC分类号： A61K38/43 ,  A61K38/16 ,  A61K31/5383 ,  A61K31/545 ,  A61K31/43 ,  A61K31/7042 ,  A61K31/431 ,  A61K31/4164 ,  A61P31/04

CPC分类号： A61K38/43 ,  A61K31/4164 ,  A61K31/43 ,  A61K31/431 ,  A61K31/5383 ,  A61K31/545 ,  A61K31/7042 ,  A61K38/16 ,  A61P31/04

摘要： The present invention relates to the field of medicine, specifically the field of bacterial infection and treatment thereof.

公开(公告)号：US20230174552A1

公开(公告)日：2023-06-08

申请号：US18097046

申请日：2023-01-13

申请人： KaNDy Therapeutics Limited

发明人： Mike TROWER ,  Monica LAZARO ,  Derek BUSH ,  David ELDER ,  Mary KERR

IPC分类号： C07D498/04 ,  A61P15/00 ,  A61K31/5383

CPC分类号： C07D498/04 ,  A61P15/00 ,  A61K31/5383 ,  C07B2200/13

摘要： The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.

公开(公告)号：US20230147517A1

公开(公告)日：2023-05-11

申请号：US18076012

申请日：2022-12-06

申请人： SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD. ,  SHANGHAI HIGHTIDE BIOPHARMACEUTICAL, LTD.

发明人： Li YU ,  James Gerry FERGUSON

IPC分类号： A61K31/573 ,  A61K9/107 ,  A61M11/00 ,  A61K9/00 ,  A61K47/32 ,  A61K31/74 ,  A61K47/28 ,  A61K47/24 ,  A61K9/16 ,  A61K31/5383 ,  A61K47/10

CPC分类号： A61K31/573 ,  A61K9/107 ,  A61M11/00 ,  A61K9/0043 ,  A61K47/32 ,  A61K31/74 ,  A61K9/0048 ,  A61K9/0046 ,  A61K47/28 ,  A61K47/24 ,  A61K9/1617 ,  A61K9/1641 ,  A61K31/5383 ,  A61K47/10 ,  A61M2210/0612 ,  A61M2210/0618 ,  A61J1/05

摘要： The invention provides liquid formulation compositions and medicament delivery devices, and methods for preparing and using the same. For example, the liquid formulation composition is an emulsion including a solvent and liquid particles, which includes surfactants and are dispersed in the solvent. The volume average particle size of the liquid particles is less than about 100 μm; the surface tension of the liquid formulation composition is less than about 60 mN/m; and the absolute value of zeta potential is greater than about 15 mV. The containment vessel may be a sprayer or a dropping device. The invention also provides methods for preparation of the liquid formulation compositions and medicament delivery devices as well as methods for using the same in treatment of various diseases and condition, for example, otitis media, otitis externa, rhinitis, sinusitis, lower respiratory tract inflammation, xerostomia (dry mouth), xerophthalmia (dry eyes) and xeromycteria (dry nose).

公开(公告)号：US20230145342A1

公开(公告)日：2023-05-11

申请号：US17917338

申请日：2021-04-07

申请人： AALTO UNIVERSITY FOUNDATION SR ,  HELSINGIN YLIOPISTO

发明人： Christopher JONKERGOUW ,  Ekaterina OSMEKHINA ,  Markus LINDER ,  Katarzyna LESKINEN ,  Päivi SAAVALAINEN

IPC分类号： A61K31/05 ,  A61K31/7036 ,  A61K31/546 ,  A61K38/12 ,  A61K31/407 ,  A61K31/5383 ,  A61K31/427 ,  A61P31/04

CPC分类号： A61K31/05 ,  A61K31/7036 ,  A61K31/546 ,  A61K38/12 ,  A61K31/407 ,  A61K31/5383 ,  A61K31/427 ,  A61P31/04

摘要： This invention relates to use of a macrocyclic cavity-containing compound sensitizing a microbe towards an antimicrobial agent. The invention also relates to use of a macrocyclic cavity-containing compound in reducing the amount of an antimicrobial agent needed to prevent or inhibit the growth of a microbe in a subject. Further, the invention relates to use of a macrocyclic cavity-containing compound in reducing the build-up of resistance of a microbe towards an anti-microbial agent. The invention also relates to a macrocyclic cavity-containing compound and an antimicrobial agent for use in inhibiting/treating/preventing a microbial infection in a subject having a microbial infection or being at risk of a microbial infection.

公开(公告)号：US20230086469A1

公开(公告)日：2023-03-23

申请号：US17638770

申请日：2019-08-30

申请人： UNIVERSIDAD DE CHILE

发明人： Juan Carlos Aguillón Gutiérrez ,  Diego Francisco Catalán Martina ,  Lilian Andrea Soto Saez ,  Jaxaira Amilene Maggi Orellana ,  Octavio Alexis Aravena Madariaga ,  Katina Schinnerling

IPC分类号： A61K39/00 ,  A61K39/39 ,  A61P37/06 ,  A61K31/519 ,  A61K31/52 ,  A61K31/4706 ,  A61K38/13 ,  A61K31/65 ,  A61K31/42 ,  A61K31/5383 ,  A61K31/655 ,  A61K33/242 ,  A61K39/395

摘要： The present invention provides an immunomodulatory composition useful for treating or preventing joint damage comprising at least a set of peptides possessing an amino acid sequence having at least 80%, 85% and 90% sequence identity with the peptides corresponding to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4 and a method for the treatment or prevention of joint damage comprising the steps of a) extract monocytes from a patient with a rheumatological disease; b) culture the monocytes extracted in the previous step in AIM-V medium with GM-CSF and IL-4; c) wash the monocytes and add dexamethasone; d) load the tDCs with the immunomodulatory composition comprising autoantigenic peptides; e) add MPLA; and f) incorporate the tDCs loaded with autoantigenic peptides into the patient. The present invention includes methods for the treatment or prevention of rheumatological disease comprising a wide range of tDCs performed by different protocols.

公开(公告)号：US11607396B2

公开(公告)日：2023-03-21

申请号：US17141070

申请日：2021-01-04

申请人： Genentech, Inc.

发明人： Snahel Patel ,  Gregory Hamilton ,  Guiling Zhao ,  Huifen Chen

IPC分类号： A61K31/16 ,  A61P9/10 ,  C07D519/00 ,  A61P9/00 ,  A61P29/00 ,  A61P43/00 ,  A61K31/396 ,  A61K31/397 ,  A61K31/4025 ,  A61K31/416 ,  A61K31/4196 ,  A61K31/44 ,  A61K31/5383 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  C07D491/048

摘要： The invention provides novel compounds having the general formula I: wherein R1, R2, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.

公开(公告)号：US20230075092A1

公开(公告)日：2023-03-09

申请号：US17792403

申请日：2021-01-12

申请人： UNIVERSITE CLAUDE BERNARD LYON 1 ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSITE LAVAL ,  SIGNIA THERAPEUTICS ,  ECOLE NORMALE SUPERIEURE DE LYON

发明人： Olivier TERRIER ,  Manuel ROSA-CALATRAVA ,  Guy BOIVIN ,  Mario-Andres PIZZORNO ,  Blandine PADEY

IPC分类号： A61K31/554 ,  A61K9/00 ,  A61K31/5383 ,  A61K45/06 ,  A61P31/16

摘要： The invention relates to a combination of Diltiazem and at least one viral polymerase inhibitor compound selected from among Baloxavir marboxil, Pimodivir, RO-7 and CC-42344. The invention relates in particular to the therapeutic use of said combination in the prevention and/or treatment of a viral infection, in particular of the respiratory and/or intestinal tract of a human or animal body.

公开(公告)号：US11572561B2

公开(公告)日：2023-02-07

申请号：US16906019

申请日：2020-06-19

申请人： City University of Hong Kong

发明人： Chi Kong Terrence Lau ,  Oi Kwan Law

IPC分类号： A61K39/108 ,  A61K39/00 ,  A61K39/38 ,  C12N15/113 ,  A61K31/7088 ,  A61K31/43 ,  A61K31/546 ,  A61K31/165 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7056 ,  A61K31/496 ,  A61K31/5383 ,  A61K31/4709 ,  A61K31/5377 ,  C12N7/00 ,  A61K9/51 ,  A61P31/04

摘要： A method of inhibiting growth of a bacterium including steps of: a) delivering a polynucleotide including a sequence of SEQ ID NO: 1 or a homologue thereof to the bacterium, and b) contacting the bacterium with an effective amount of an antibiotic; wherein the bacterium is Pseudomonas aeruginosa. A method of treating a subject suffering from an infection caused by a bacterium which is Pseudomonas aeruginosa and the method including steps of: i) delivering said polynucleotide to a tissue infected by the bacterium or a bacterial cell in the subject; and ii) administering an effective amount of an antibiotic to the subject. A composition and a recombinant plasmid containing said polynucleotide.

公开(公告)号：US20230021705A1

公开(公告)日：2023-01-26

申请号：US17723758

申请日：2022-04-19

申请人： Gilead Sciences, Inc.

发明人： Megan K. Armstrong ,  Gediminas J. Brizgys ,  James S. Cassidy ,  Elbert Chin ,  Chienhung Chou ,  Chao-I Hung ,  David W. Lin ,  Michael L. Mitchell ,  Ezra Roberts ,  Scott D. Schroeder ,  James G. Taylor ,  Rhiannon Thomas-Tran ,  Nathan E. Wright ,  Zheng-Yu Yang

IPC分类号： A61K31/5383 ,  C07D417/14 ,  C07D405/14 ,  C07D498/04 ,  C07D413/14 ,  C07D513/04 ,  C07D471/04 ,  C07D487/04 ,  C07D409/14 ,  C07D401/14 ,  C07D491/08 ,  C07D495/04 ,  A61K45/06 ,  A61K31/423 ,  A61K31/137 ,  A61K31/357 ,  A61K31/135 ,  A61K38/22 ,  A61K31/5375 ,  A61K31/4188 ,  A61K35/60 ,  A61K31/4439 ,  A61K31/437 ,  A61K31/519 ,  A61K31/4985 ,  A61K31/444 ,  A61K31/4995 ,  A61K31/497 ,  A61K31/5377 ,  A61K31/4545 ,  C07D401/10 ,  A61K31/427 ,  A61K31/433 ,  C07D403/12

摘要： The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.